Cargando…
Immune response treated with bone marrow mesenchymal stromal cells after stroke
Stroke is a leading cause of death and long-term disability worldwide. Tissue plasminogen activator (tPA) is an effective treatment for ischemic stroke. However, only a small part of patients could benefit from it. Therefore, finding a new treatment is necessary. Bone marrow mesenchymal stromal cell...
Autores principales: | Wang, Zili, Wang, Xudong, Liao, Yidong, Chen, Guangtang, Xu, Kaya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530191/ https://www.ncbi.nlm.nih.gov/pubmed/36203971 http://dx.doi.org/10.3389/fneur.2022.991379 |
Ejemplares similares
-
World-Wide Efficacy of Bone Marrow Derived Mesenchymal Stromal Cells in Preclinical Ischemic Stroke Models: Systematic Review and Meta-Analysis
por: Satani, Nikunj, et al.
Publicado: (2019) -
Peripheral blood monocytes as a therapeutic target for marrow stromal cells in stroke patients
por: Satani, Nikunj, et al.
Publicado: (2022) -
Serial Cerebral Metabolic Changes in Patients With Ischemic Stroke Treated With Autologous Bone Marrow Derived Mononuclear Cells
por: Haque, Muhammad E., et al.
Publicado: (2019) -
Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases
por: Pan, Kuang, et al.
Publicado: (2019) -
Bone Marrow Mesenchymal Stromal Cells: Identification, Classification, and Differentiation
por: Gao, Qianmin, et al.
Publicado: (2022)